Found: 59
Select item for more details and to access through your institution.
Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1649, doi. 10.1007/s10637-021-01125-2
- By:
- Publication type:
- Article
Differential Efficacy of Targeted Monoclonal Antibodies in Left-Sided Colon and Rectal Metastatic Cancers.
- Published in:
- Clinical Colorectal Cancer, 2023, v. 22, n. 3, p. 298, doi. 10.1016/j.clcc.2023.05.002
- By:
- Publication type:
- Article
A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial).
- Published in:
- 2020
- By:
- Publication type:
- journal article
Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLUE] Study).
- Published in:
- 2016
- By:
- Publication type:
- journal article
Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G).
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11199-1
- By:
- Publication type:
- Article
Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.688709
- By:
- Publication type:
- Article
Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS)
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2021.576036
- By:
- Publication type:
- Article
Combination of Oxaliplatin and 5-Fluorouracil/Leucovorin for Advanced Esophageal Squamous Cell Carcinoma Refractory or Intolerant to Standard Therapies.
- Published in:
- Case Reports in Oncology, 2019, v. 12, n. 1, p. 304, doi. 10.1159/000499705
- By:
- Publication type:
- Article
Clinical and microbiological features of obstructive cholangitis with bloodstream infection caused by Pandoraea apista identified by MALDI-TOF mass spectrometry and ribosomal RNA sequencing in a cancer patient.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Survival Outcomes of Resected BRAF V600E Mutant Colorectal Liver Metastases: A Multicenter Retrospective Cohort Study in Japan.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2020, v. 27, n. 9, p. 3307, doi. 10.1245/s10434-020-08817-8
- By:
- Publication type:
- Article
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
- Published in:
- British Journal of Cancer, 2023, v. 128, n. 10, p. 1897, doi. 10.1038/s41416-023-02212-2
- By:
- Publication type:
- Article
Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08.
- Published in:
- 2020
- By:
- Publication type:
- journal article
A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory to Standard Therapies.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Correction to: Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC‑06).
- Published in:
- 2018
- By:
- Publication type:
- Correction Notice
Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06).
- Published in:
- Gastric Cancer, 2018, v. 21, n. 3, p. 421, doi. 10.1007/s10120-017-0766-x
- By:
- Publication type:
- Article
Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in Refractory Metastatic Colorectal Cancer.
- Published in:
- Oncology, 2017, v. 93, n. 5, p. 329, doi. 10.1159/000479280
- By:
- Publication type:
- Article
Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody.
- Published in:
- Oncology, 2017, v. 92, n. 4, p. 205, doi. 10.1159/000453336
- By:
- Publication type:
- Article
Correlation between human epidermal growth factor receptor 2 expression level and efficacy of trastuzumab beyond progression in metastatic gastric cancer.
- Published in:
- Oncology Letters, 2017, v. 14, n. 2, p. 2545, doi. 10.3892/ol.2017.6409
- By:
- Publication type:
- Article
A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study.
- Published in:
- Ecancermedicalscience, 2018, v. 12, n. 844-874, p. 1, doi. 10.3332/ecancer.2018.847
- By:
- Publication type:
- Article
Risk factors affecting delay of initiating adjuvant chemotherapy for stage III colorectal cancer.
- Published in:
- International Journal of Clinical Oncology, 2024, v. 29, n. 9, p. 1293, doi. 10.1007/s10147-024-02567-3
- By:
- Publication type:
- Article
Survival impact of sequential chemotherapy following pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma.
- Published in:
- International Journal of Clinical Oncology, 2024, v. 29, n. 6, p. 764, doi. 10.1007/s10147-024-02508-0
- By:
- Publication type:
- Article
Nivolumab versus irinotecan as third- or later-line treatment for advanced gastric cancer: a multi-center retrospective study.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 6, p. 756, doi. 10.1007/s10147-023-02330-0
- By:
- Publication type:
- Article
Clinical outcomes of patients diagnosed with cancer of unknown primary or malignancy of undefined primary origin who were referred to a regional cancer center.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 5, p. 644, doi. 10.1007/s10147-023-02316-y
- By:
- Publication type:
- Article
Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer.
- Published in:
- International Journal of Clinical Oncology, 2021, v. 26, n. 11, p. 2025, doi. 10.1007/s10147-021-02004-9
- By:
- Publication type:
- Article
Phase I study of napabucasin in combination with FOLFIRI + bevacizumab in Japanese patients with metastatic colorectal cancer.
- Published in:
- International Journal of Clinical Oncology, 2021, v. 26, n. 11, p. 2017, doi. 10.1007/s10147-021-01987-9
- By:
- Publication type:
- Article
A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study.
- Published in:
- International Journal of Clinical Oncology, 2021, v. 26, n. 4, p. 701, doi. 10.1007/s10147-020-01842-3
- By:
- Publication type:
- Article
Second-line chemotherapy using taxane in patients with advanced gastric cancer who presented with severe peritoneal metastasis: a multicenter retrospective study.
- Published in:
- International Journal of Clinical Oncology, 2021, v. 26, n. 2, p. 355, doi. 10.1007/s10147-020-01802-x
- By:
- Publication type:
- Article
Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma.
- Published in:
- International Journal of Clinical Oncology, 2020, v. 25, n. 5, p. 972, doi. 10.1007/s10147-020-01618-9
- By:
- Publication type:
- Article
Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
- Published in:
- International Journal of Clinical Oncology, 2020, v. 25, n. 4, p. 614, doi. 10.1007/s10147-019-01600-0
- By:
- Publication type:
- Article
Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.
- Published in:
- International Journal of Clinical Oncology, 2016, v. 21, n. 5, p. 890, doi. 10.1007/s10147-016-0963-3
- By:
- Publication type:
- Article
Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 3, p. 1123, doi. 10.1007/s00432-022-03979-2
- By:
- Publication type:
- Article
Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study.
- Published in:
- Oncologist, 2023, v. 28, n. 11, p. e1108, doi. 10.1093/oncolo/oyad143
- By:
- Publication type:
- Article
The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study.
- Published in:
- Oncologist, 2021, v. 26, n. 10, p. 845, doi. 10.1002/onco.13870
- By:
- Publication type:
- Article
Phase I Study of Alternate‐Day Administration of S‐1, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer.
- Published in:
- Oncologist, 2020, v. 25, n. 11, p. e1614, doi. 10.1634/theoncologist.2020-0463
- By:
- Publication type:
- Article
A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer.
- Published in:
- Oncologist, 2019, v. 24, n. 2, p. 159, doi. 10.1634/theoncologist.2018-0580
- By:
- Publication type:
- Article
Risk of second primary malignancies after definitive treatment for esophageal cancer: A competing risk analysis.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 1, p. 394, doi. 10.1002/cam4.2688
- By:
- Publication type:
- Article
The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation.
- Published in:
- Therapeutic Advances in Medical Oncology, 2019, v. 11, p. 1, doi. 10.1177/1758835918820298
- By:
- Publication type:
- Article
The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation.
- Published in:
- Therapeutic Advances in Medical Oncology, 2019, v. 11, p. N.PAG, doi. 10.1177/1758835918820298
- By:
- Publication type:
- Article
Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Open versus laparoscopic surgery for primary appendiceal tumors: a large multicenter retrospective propensity score-matched cohort study in Japan.
- Published in:
- Surgical Endoscopy & Other Interventional Techniques, 2021, v. 35, n. 10, p. 5515, doi. 10.1007/s00464-020-08046-w
- By:
- Publication type:
- Article
Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer.
- Published in:
- Drugs - Real World Outcomes, 2023, v. 10, n. 3, p. 405, doi. 10.1007/s40801-023-00366-2
- By:
- Publication type:
- Article
The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 11, p. 2184, doi. 10.1002/cam4.4599
- By:
- Publication type:
- Article
Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial.
- Published in:
- Japanese Journal of Clinical Oncology, 2019, v. 49, n. 4, p. 339, doi. 10.1093/jjco/hyy189
- By:
- Publication type:
- Article
Topical corticosteroid therapy for facial acneiform eruption due to EGFR inhibitors in metastatic colorectal cancer patients: a randomized controlled trial comparing starting with a very strong or a weak topical corticosteroid (FAEISS study, NCCH1512, colorectal part).
- Published in:
- Supportive Care in Cancer, 2022, v. 30, n. 5, p. 4497, doi. 10.1007/s00520-022-06874-1
- By:
- Publication type:
- Article
Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2015, v. 76, n. 2, p. 357, doi. 10.1007/s00280-015-2806-8
- By:
- Publication type:
- Article
Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study.
- Published in:
- 2019
- By:
- Publication type:
- journal article